Skip to content Skip to footer
AstraZeneca & Alteogen

AstraZeneca and Alteogen Enter an Exclusive License Deal for ALT-B4 to Develop & Market Subcutaneous Formulations of Multiple Oncology Drugs

Shots:Alteogen has granted AstraZeneca global rights of ALT-B4 to develop & commercialize SC formulations of multiple oncology assets, while Alteogen will be responsible for clinical & commercial supply of ALT-B4 As per the deal, Alteogen will receive an upfront, along with development, regulatory, & sales milestones, plus royalties on sale of commercialized products…

Read more

Viewpoints_Kasper Roet 

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

Shots: Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds. QurAlis received an up front payment of $45M plus an additional equity investment. The company is…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]